Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1G>A mutation

International Journal of Cancer

Volumn 101, Issue 3, 2002, Pages 253-258

  Van Kuilenburg, André B P ^a,b   Meinsma, Rutger ^a   Zoetekouw, Lida ^a   Van Gennip, Albert H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Neutropenia; Pharmacogenetics

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; EVALUATION AND FOLLOW UP; FEMALE; GENDER; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); EXONS; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENOTYPE; GRANULOCYTES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS; NEUTROPENIA; OXIDOREDUCTASES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; RNA SPLICE SITES;

EID: 0037144354     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10599     Document Type: Article

References (32)

1. Efficacy of intravenous continuous infusion of 15-fluorouracil compared with bolus administration in advanced colorectal cancer
2. Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer
3. 5-Fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer
4. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
5. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
6. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer - Status of the art
7. Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile
8. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
9. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
10. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen
11. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy
12. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
13. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
14. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity
15. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
16. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
17. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency
18. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
19. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified patients, and clinical implication in 5-fluorouracil chemotherapy
20. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
21. Population study of dihydropyrimidine dehydrogenase in cancer patients
22. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
23. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
24. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
25. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure
26. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency
27. Measurement of protein using bicinchoninic acid
28. Retrospective study - The odds ratio
29. Preferential activation of capecitabine in tumor following oral administration to colorectal patients
30. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
31. Influence of sex and age on fluorouracil clearance
32. Autoregulation of 5-fluorouracil metabolism